JBM (Healthcare) (HKSE:02161) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02161 JBM (Healthcare) Ltd HKSE:02161
86 GF Score
Price HK$1.84
GF Value HK$2.09
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is JBM (Healthcare) Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HKSE:02161
86GF Score
JBM (Healthcare) Ltd HKSE:02161
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?

Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued. The current stock price of HK$1.84 is trading 12% below its estimated GF Value™ of HK$2.09. GuruFocus considers JBM (Healthcare) to be Modestly Undervalued.

Key valuation signals for HKSE:02161:

  • Dividends Received:
  • GF Value™: HK$2.09 vs. price of HK$1.84 (12% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JBM (Healthcare) Business Description

Address 108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score

Get the complete analysis for HKSE:02161

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.84
Price
HK$2.09
GF Value